Equities

Forecasts data is unavailable for this security.

Consensus recommendation

As of Jul 14, 2017, the consensus forecast amongst 30 polled investment analysts covering GlaxoSmithKline plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Sep 13, 2016. The previous consensus forecast advised investors to hold their position in GlaxoSmithKline plc.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy6
Outperform9
Hold13
Underperform1
Sell1

Share price forecast

The 27 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,775.00, with a high estimate of 2,200.00 and a low estimate of 1,300.00. The median estimate represents a 9.91% increase from the last price of 1,615.00.
High36.2%2,200.00
Med9.9%1,775.00
Low-19.5%1,300.00

Dividends

In 2016, GlaxoSmithKline PLC reported a dividend of 0.80 GBP, equaling last years dividend. The 25 analysts covering the company expect dividends of 0.80 GBP for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates

On Apr 26, 2017, GlaxoSmithKline plc reported 1st quarter 2017 earnings of 0.25 per share. This result was in line with the consensus of the 13 analysts following the company and exceeded last year's 1st quarter results by 26.26%.
The next earnings announcement is expected on Jul 26, 2017.
Average growth rate+7.92%
GlaxoSmithKline plc reported annual 2016 earnings of 1.02 per share on Feb 08, 2017.
The next earnings announcement from GlaxoSmithKline plc is expected the week of Feb 05, 2018.
Average growth rate-0.19%
More ▼

Revenue history & estimates

GlaxoSmithKline plc had 1st quarter 2017 revenues of 7.38bn. This bettered the 7.26bn consensus of the 13 analysts covering the company. This was 18.54% above the prior year's 1st quarter results.
Average growth rate+4.56%
GlaxoSmithKline plc had revenues for the full year 2016 of 27.89bn. This was 16.58% above the prior year's results.
Average growth rate+1.91%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.